Study populations CANVAS Program The CANVAS Program, which integrated the CANVAS and CANVAS-R trials, investigated the effects of canagliflozin on CV, renal and safety outcomes in 10,142 patients with T2D and either established CV disease or at high CV risk, with a mean follow-up time of 188 weeks. Details of the CANVAS Program design have been published [11, 12].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with McKean
Contact McKean, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack